In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
about
Current concepts in antimicrobial therapy against resistant gram-negative organisms: extended-spectrum beta-lactamase-producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, and multidrug-resistant Pseudomonas aeruginosaThe 1.4 Å Crystal Structure of the Class D β-Lactamase OXA-1 Complexed with DoripenemPopulation pharmacokinetics of doripenem based on data from phase 1 studies with healthy volunteers and phase 2 and 3 studies with critically ill patients.Open-Label Study To Evaluate the Single-Dose Pharmacokinetics, Safety, and Tolerability of Doripenem in Infants Less than 12 Weeks in Chronological AgeEssentials for selecting antimicrobial therapy for intra-abdominal infectionsIn vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa.Antimicrobial resistance of aerobes and facultative anaerobes isolated from the oral cavity.Doripenem: position in clinical practice.Update on the treatment of Pseudomonas aeruginosa pneumonia.Treatment options for multidrug-resistant nonfermenters.Pharmacokinetic evaluation of piperacillin-tazobactam.In vitro antibacterial activity of doripenem against clinical isolates from French teaching hospitals: proposition of zone diameter breakpoints.In vitro activity studies of doripenem and two other carbapenems tested against Pseudomonas aeruginosa and other non-fermentative bacilli.Ceftazidime for respiratory infections.Pharmacodynamics of the antibacterial effect of and emergence of resistance to doripenem in Pseudomonas aeruginosa and Acinetobacter baumannii in an in vitro pharmacokinetic model.Worldwide experience with the use of doripenem against extended-spectrum-beta-lactamase-producing and ciprofloxacin-resistant Enterobacteriaceae: analysis of six phase 3 clinical studiesCharacteristics of doripenem: a new broad-spectrum antibiotic.Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.Doripenem dosing recommendations for critically ill patients receiving continuous renal replacement therapy.Predictability of doripenem susceptibility in Acinetobacter baumannii isolates based on other carbapenem susceptibilities and bla OXA gene status.Pharmacokinetics, safety, and tolerability of doripenem after 0.5-, 1-, and 4-hour infusions in healthy volunteers.Successful treatment with doripenem and tobramycin of ventriculitis due to imipenem- and meropenem-resistant Pseudomonas aeruginosa.Assessment of Doripenem, Meropenem, and Imipenem against Respiratory Isolates of Pseudomonas aeroginosa in a Tertiary Care Hospital of North India.Therapies for multidrug resistant and extensively drug-resistant non-fermenting gram-negative bacteria causing nosocomial infections: a perilous journey toward 'molecularly targeted' therapy.Molecular characterization of oxacillinases and genotyping of invasive Acinetobacter baumannii isolates using repetitive extragenic palindromic sequence-based polymerase chain reaction in Ankara between 2004 and 2010.
P2860
Q24612271-377AB6C2-CB6E-45DB-90D4-C78803BE7C90Q27658215-A3A4A4DF-9648-4751-9878-3A1876BEE28EQ33553063-6521B400-F5C5-4B62-AAA6-B3177A05F642Q35859870-2FA9F96C-B210-413D-9C56-42A157E1E394Q36649011-1C7F6081-448E-49A5-AF3D-53C4710733FBQ37392734-40D487C7-2B52-41EE-A9F0-6598C90CB58CQ37437466-C3AF13D8-DC55-45C6-A2C7-9EBB64B4C10DQ37503320-178F9476-C0C9-45CB-9591-214E40E2615FQ37516904-85A18233-1D04-4F3E-B132-CDDE2AF77B1FQ37700555-FFFB90E0-DC20-4C87-BBFA-E2AFB06C941CQ37773368-E74023C5-0122-461F-945A-944FC0F58773Q37810794-9224DD93-97D9-4DD3-9191-0735A825E912Q37974745-2F4974FF-B136-47CF-B6E7-5F5AF8EDC8C0Q38040144-D46C3A95-05BD-4F8C-A391-B9C158EEFCF2Q39599930-C7E1EA71-C9E0-4F65-A0E9-39A8DAEF79B8Q40337526-FE9CC6B5-4196-48B6-92A5-9E4254C8F06FQ42049594-7E56D7A0-49ED-44A4-AE90-38A78D09DAC8Q42099309-FEA45F78-B10C-48CD-8497-3FF6E3195323Q42257467-C961DF2B-B520-4BC2-9742-73EA7E653A42Q43119954-1404FB1A-583D-4EA9-B854-E78908738D9DQ45954223-FEA5F424-2FED-4976-A4A6-D5A32D17D979Q46049860-5FCAA867-B893-48B0-9646-C5FA373F7143Q47094533-5ED82C4B-4478-4A97-946E-DB0ABB5BDA5EQ47661746-D26164FA-2927-4BA9-B080-8AB8CFC3E19DQ50911463-930BE292-BD17-4567-B883-916F9A942AED
P2860
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
In vitro activity of doripenem ...... olates from the United States.
@en
type
label
In vitro activity of doripenem ...... olates from the United States.
@en
prefLabel
In vitro activity of doripenem ...... olates from the United States.
@en
P2093
P2860
P921
P356
P1476
In vitro activity of doripenem ...... olates from the United States.
@en
P2093
Chris M Pillar
Daniel F Sahm
Dineshchandra Shah
Mohana K Torres
Nina P Brown
P2860
P304
P356
10.1128/AAC.00381-08
P407
P577
2008-09-08T00:00:00Z